Osteoblastic metastases from breast carcinoma with false-negative bone scan

Pl, Munk; Py, Poon; Jx, O'Connell; Janzen, D L; Coupland, David B.; Js, Kwong; Gelmon, Karen A.; Worsley, Dan

doi:10.1007/s002560050262

Cited by 11 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 However, falsenegative results have been documented even in osteoblastic metastases. 6,7 The study showed that bone scintigraphy was not sensitive to detect micrometastases (2.3%) or more extensive intertrabecular metastases (3.3%). In addition, osteoblastic metastases were detected in only 57.6%.…”

Section: Radiological Imagingmentioning

confidence: 98%

Intertrabecular Vertebral Metastases: Metastases Only Detectable on MR Imaging

Yamaguchi

2001

Semin Musculoskelet Radiol

View full text Add to dashboard Cite

Metastatic intertrabecular vertebral tumors that infiltrate the marrow space without trabecular bone alteration are not visible on radiographs or bone scans. To understand the clinical importance of intertrabecular metastases, their histological and radiological aspects were reviewed based on an examination using 69 cadavers. Metastatic tumors were found in 940 of 1653 vertebral bodies. Radiography of the specimen demonstrated lesions in 485 of 940 vertebral bodies (51.6%). Bone scintigraphy showed lesions in 109 of 415 vertebral bodies (26.3%) with tumors examined within 3 months before autopsy, whereas magnetic resonance (MR) images detected 132 of 146 (90.4%) lesions. The intertrabecular metastases were found in 36.9% of the metastatic lesions and was difficult to see on radiography (5.8%) and bone scans (3.3%) whereas MR images detected most of them (94.6%). The intertrabecular metastasis is the most common type of skeletal metastases and is only detectable on MR images.

show abstract

Section: Radiological Imagingmentioning

confidence: 98%

Intertrabecular Vertebral Metastases: Metastases Only Detectable on MR Imaging

Yamaguchi

2001

Semin Musculoskelet Radiol

View full text Add to dashboard Cite

show abstract

“…Specifically, CaP skeletal metastases are most often radiographically characterized as osteoblastic (i.e., increased mineral density at the site of the lesion) as opposed to osteolytic. Other tumors, such as breast cancer, can form osteoblastic lesions; however, these occur less frequently [Munk et al, 1997; Yamashita et al, 2000]. In spite of the radiographic osteoblastic appearance it is clear from histological evidence that CaP metastases form a heterogeneous mixture of osteolytic and osteoblastic lesions although osteoblastic lesions are predominant [Urwin et al, 1985; Percival et al, 1987; Berruti et al, 1996; Vinholes et al, 1996; Roudier et al, 2000].…”

mentioning

confidence: 99%

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

Keller

Brown

2003

J of Cellular Biochemistry

251

215

View full text Add to dashboard Cite

Advanced prostate cancer is frequently accompanied by the development of metastasis to bone. In the past, prostate cancer bone metastases were characterized as being osteoblastic (i.e., increasing bone density) based on radiographs. However, emerging evidence suggests that development of prostate cancer bone metastases requires osteoclastic activity in addition to osteoblastic activity. The complexities of how prostate tumor cells influence bone remodeling are just beginning to be elucidated. Prostate cancer cells produce a variety of pro-osteoblastic factors that promote bone mineralization. For example, both bone morphogenetic proteins and endothelin-1 have well recognized pro-osteoblastic activities and are produced by prostate cancer cells. In addition to factors that enhance bone mineralization prostate cancer cells produced factors that promote osteoclast activity. Perhaps the most critical pro-osteoclastogenic factor produced by prostate cancer cells is receptor activator of NFkappaB ligand (RANKL), which has been shown to be required for the development of osteoclasts. Blocking RANKL results in inhibiting prostate cancer-induced osteoclastogenesis and inhibits development and progression of prostate tumor growth in bone. These findings suggest that targeting osteoclast activity may be of therapeutic benefit. However, it remains to be defined how prostate cancer cells synchronize the combination of osteoclastic and osteoblastic activity. We propose that as the bone microenvironment is changed by the developing cancer, this in turn influences the prostate cancer cells' balance between pro-osteoclastic and pro-osteoblastic activity. Accordingly, the determination of how the prostate cancer cells and bone microenvironment crosstalk are important to elucidate how prostate cancer cells modulate bone remodeling.

show abstract

“…Specifically, prostate carcinoma skeletal metastases are most often characterized as osteoblastic (i.e., increased mineral density at the site of the lesion) as opposed to osteolytic. Other tumors, such as breast cancer, can form osteoblastic lesions; however, these occur less frequently [67,68].…”

Section: Prostate Skeletal Metastases Are Mixed Osteoblastic and Osteolytic Lesionsmentioning

confidence: 99%

Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone

Keller¹,

Zhang²,

Cooper

et al.

Prostate Cancer: New Horizons in Research and Treatment

View full text Add to dashboard Cite

The majority of men with progressive prostate cancer develop metastases with the skeleton being the most prevalent metastatic site. Unlike many other tumors that metastasize to bone and form osteolytic lesions, prostate carcinomas form osteoblastic lesions. However, histological evaluation of these lesions reveals the presence of underlying osteoclastic activity. These lesions are painful, resulting in diminished quality of life of the patient. There is emerging evidence that prostate carcinomas establish and thrive in the skeleton due to cross-talk between the bone microenvironment and tumor cells. Bone provides chemotactic factors, adhesion factors, and growth factors that allow the prostate carcinoma cells to target and proliferate in the skeleton. The prostate carcinoma cells reciprocate through production of osteoblastic and osteolytic factors that modulate bone remodeling. The prostate carcinoma-induced osteolysis promotes release of the many growth factors within the bone extracellular matrix thus further enhancing the progression of the metastases. This review focuses on the interaction between the bone and the prostate carcinoma cells that allow for development and progression of prostate carcinoma skeletal metastases.

show abstract

Osteoblastic metastases from breast carcinoma with false-negative bone scan

Cited by 11 publications

References 4 publications

Intertrabecular Vertebral Metastases: Metastases Only Detectable on MR Imaging

Intertrabecular Vertebral Metastases: Metastases Only Detectable on MR Imaging

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone

Contact Info

Product

Resources

About